Prenatal Diagnosis of Fetuses With Increased Nuchal Translucency by Genome Sequencing Analysis

Kwong Wai Choy1,2,3†, Huilin Wang4†, Mengmeng Shi1†, Jingsi Chen5†, Zhenjun Yang1, Rui Zhang4, Huanchen Yan5, Yanfang Wang4, Shaoyun Chen4, Matthew Hoi Kin Chau1, Ye Cao1, Olivia Y.M. Chan1, Yvonne K. Kwok1, Yuanfang Zhu4, Min Chen5, Tak Yeung Leung1,2,3 and Zirui Dong1,2,5*

1 Department of Obstetrics & Gynaecology, The Chinese University of Hong Kong, Hong Kong, China, 2 Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, China, 3 The Chinese University of Hong Kong-Baylor College of Medicine Joint Center for Medical Genetics, Hong Kong, China, 4 Department of Central Laboratory, Ba’an Maternity and Child Healthcare Hospital Affiliated to Jinan University School of Medicine, Key Laboratory of Birth Defects Research, Birth Defects Prevention Research and Transformation Team, Shenzhen, China, 5 Department of Obstetrics and Gynecology, Key Laboratory of Reproduction and Genetics of Guangdong Higher Education Institutes, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China, 6 Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, United States

Background: Increased nuchal translucency (NT) is an important biomarker associated with increased risk of fetal structural anomalies. It is known to be contributed by a wide range of genetic etiologies from single-nucleotide variants to those affecting millions of base pairs. Currently, prenatal diagnosis is routinely performed by karyotyping and chromosomal microarray analysis (CMA); however, both of them have limited resolution. The diversity of the genetic etiologies warrants an integrated assay such as genome sequencing (GS) for comprehensive detection of genomic variants. Herein, we aim to evaluate the feasibility of applying GS in prenatal diagnosis for the fetuses with increased NT.

Methods: We retrospectively applied GS (> 30-fold) for fetuses with increased NT (≥3.5 mm) who underwent routine prenatal diagnosis. Detection of single-nucleotide variants, copy number variants, and structural rearrangements was performed simultaneously, and the results were integrated for interpretation in accordance with the guidelines of the American College of Medical Genetics and Genomics. Pathogenic or likely pathogenic (P/LP) variants were selected for validation and parental confirmation, when available.

Results: Overall, 50 fetuses were enrolled, including 34 cases with isolated increased NT and 16 cases with other fetal structural malformations. Routine CMA and karyotyping reported eight P/LP CNVs, yielding a diagnostic rate of 16.0% (8/50). In comparison, GS provided a twofold increase in diagnostic yield (32.0%, 16/50), including one mosaic Turner syndrome, eight cases with microdeletions/microduplications, and seven cases with P/LP point mutations. Moreover, GS identified two cryptic insertions and two inversions. Follow-up study further demonstrated the potential pathogenicity of an apparently balanced insertion that disrupted an OMIM autosomal dominant disease-causing gene at the insertion site.
Conclusions: Our study demonstrates that applying GS in fetuses with increased NT can comprehensively detect and delineate the various genomic variants that are causative to the diseases. Importantly, prenatal diagnosis by GS doubled the diagnostic yield compared with routine protocols. Given a comparable turnaround time and less DNA required, our study provides strong evidence to facilitate GS in prenatal diagnosis, particularly in fetuses with increased NT.

Keywords: increased nuchal translucency, genome sequencing, prenatal diagnosis, genomic variants, structural rearrangement

INTRODUCTION

Detection of fetuses with increased nuchal translucency (NT) in routine first-trimester ultrasound screening has been widely used as a sensitive indication for fetal chromosomal abnormalities and/or fetal structural anomalies, such as congenital heart disorders or neurodevelopmental anomalies detected in later gestations (Leung et al., 2011; Huang et al., 2014; Socolov et al., 2017; Sinajon et al., 2019). Fetuses with increased NT and structural malformations are frequently contributed by genetic abnormalities and have poor prognoses. However, more than 80% of such cases do not obtain a causative result with the current routine prenatal diagnostic tests (Leung et al., 2011; Huang et al., 2014; Yang et al., 2017; Sinajon et al., 2019), challenging genetic counseling and clinical management. In addition, pathogenic copy number variants (CNVs) only account for 0.8% to 5.3% of these fetuses with isolated increased NT (with/without other soft markers) (Leung et al., 2011; Huang et al., 2014), and part of these cases would also have poor outcomes. Therefore, a test for the comprehensive detection of disease associated genomic variants including numerical disorders, structural rearrangements, CNVs, and point mutations in this prenatal cohort is warranted.

In prenatal diagnosis, quantitative fluorescent PCR (QF-PCR) is routinely conducted for the detection of maternal cell contamination (MCC) and common aneuploidy [such as Trisomy 21 (Choy et al., 2014; Sinajon et al., 2019)]. In addition, since 2010, chromosomal microarray analysis (CMA) has been recommended as the first-tier test for high-risk pregnancies in identification of microscopic or submicroscopic CNVs (Leung et al., 2011; Huang et al., 2014; Chau et al., 2019; Sinajon et al., 2019). However, this approach is limited by its resolution and it cannot detect single-nucleotide variants (SNVs) and small insertions/deletions (InDels). Owing to the breakthrough of molecular technologies such as next-generation sequencing and its reduction of costs over the years, whole-exome sequencing (or exome sequencing, WES) has been applied for both research purposes and clinical use (Drury et al., 2015; Fu et al., 2018; Leung et al., 2018; Normand et al., 2018; Lord et al., 2019; Petrovski et al., 2019). Emerging studies show that WES has the ability to provide genetic diagnoses ranging from 9.1% to 32% for the fetuses with a structural anomaly (Drury et al., 2015; Fu et al., 2018; Leung et al., 2018; Normand et al., 2018; Lord et al., 2019; Petrovski et al., 2019), while among these cases, WES yielded diagnoses in 3.2% to 21% of the fetuses with increased NT with/without structural malformations (Drury et al., 2015; Lord et al., 2019; Petrovski et al., 2019). However, most of these studies were conducted on prenatal cohorts after the exclusion of abnormal karyotypes and/or CMA results attributed to the cost and the limited ability of WES in CNV detection (Belkadi et al., 2015). These studies show the clinical utility of WES and CMA in prenatal diagnosis and warrants a combination of these two approaches for each case. Meanwhile, both WES and CMA are unable to detect apparently balanced structural rearrangements (or structural variants, SVs), a common limitation of the current methods, but some of these rearrangements have been demonstrated to be disease-causing (Talkowski et al., 2012a). The wide spectrum of genetic etiologies in fetuses with increased NT ranging from single-base mutations to those affecting millions of base pairs and numerical disorders warrants a holistic approach for comprehensive detection of the disease-causing genetic variants.

Our previous studies have demonstrated the feasibility and potential diagnostic utility of applying low-pass whole-genome sequencing (or genome sequencing, GS) analysis for the detection of CNVs (Dong et al., 2016; Dong et al., 2017) and chromosomal structural rearrangements (Dong et al., 2014) including balanced translocations and inversions in both clinical cohorts and presumably normal populations in the 1000 Genomes Project (Dong et al., 2018a; Dong et al., 2018b). By increasing the read depth to a minimal of 30-fold for the purpose of including SNV/InDel detection, GS is able to provide comprehensive detection of various genomic variants, thus providing a unique platform for gene discovery and potential clinical application. However, evaluation of its clinical utility is warranted.

Herein, we aimed to apply GS for the investigation of genetic contributions to fetuses with increased NT with/without structural malformations and to evaluate the possibility for its potential clinical application.

MATERIALS AND METHODS

Ethics, Consent, and Permissions

The study protocol was approved by the Ethics Committee of the Joint Chinese University of Hong Kong–New Territories East Cluster Clinical Research Ethics Committee (CREC Ref. No. 2016.713), Jinan University and Guangzhou Medical University. From year 2014 to 2018, 50 pregnant women, whose fetus was diagnosed with increased NT (≥3.5 mm) with/without structural
malformations (Leung et al., 2011; Huang et al., 2014) and had undergone prenatal diagnosis by CMA (and karyotyping if available) after a negative finding from QF-PCR (Choy et al., 2014), were recruited in this study. The recruitment criteria included fetuses with increased NT detected, and CMA results were available without the selection of 1) whether any fetal malformation was detected, 2) the results from CMA and/or karyotyping, 3) the timing for sample collection (CVS or AF), and 4) the pregnancy outcome (such as terminated pregnancies or live births) (Figure 1). Written informed consent was obtained from each participant for the purpose of this study, and any findings from the genome sequencing would not be disclosed to the patients. Routine CMA results were available in all cases and 90.0% (45/50) of them also had G-banded chromosome analysis results. Among them, chorionic villus sampling (CVS) was conducted for 37 cases at the time of first-trimester ultrasound screening, while amniotic fluid (AF) was obtained in the other 13 cases during the second trimester. Parental peripheral blood samples were collected at the time of prenatal sample retrieval if available.

DNA Preparation
Genomic DNA from chorionic villi or amniotic fluids (AF) were extracted using the DNeasy Blood & Tissue Kit (Cat No./ID: 69506, Qiagen, Hilden, Germany) at the time of routine CMA testing. DNA was quantified with the Quant-iT dsDNA HS Assay kit (Invitrogen, Carlsbad, CA), and DNA integrity was assessed by agarose gel electrophoresis and subsequently subjected to QF-PCR.

CMA and Karyotyping for Routine Prenatal Diagnosis
Two CMA platforms were routinely used in our three prenatal genetic diagnosis centers: CytoScan 750K (Applied Biosystems,
Affymetrix, Inc., Santa Clara, CA) and a well-established 8x60K fetal DNA chip (Agilent Technologies, Santa Clara, CA).

For the CytoScan 750K SNP-based platform, 250 ng of DNA samples was required and the experiment was conducted based on the manufacturer’s protocol (Lin et al., 2015). Aberration analysis was performed with the ChAS 2.0 software (Affymetrix) (Lin et al., 2015). For fetal DNA chip array-based comparative genomic hybridization (aCGH) platform (Leung et al., 2011), the experiment was conducted with a total of 300 ng of DNA after treatment with RNase A (Qiagen) as input, and data analysis was performed with CytoGenomics software according to the manufacturer’s protocol (Leung et al., 2011).

In 90.0% (45/50) of the cases, routine G-banded chromosome analysis of the CVS or AF was also performed by certified Medical Technologists/Cytogeneticists following international guidelines (Standards and Guidelines for Clinical Genetics Laboratories (Section 5.1) of the American College of Medical Genetics and Genomics (ACMG) and Requirements for Cytogenetic Testing of the National Pathology Accreditation Advisory Council). A minimum of two independent cultures were set up for each specimen and 15–20 metaphases were analyzed with two metaphases karyotyped at a resolution of 400 bands. In cases suspected of mosaicism, at least 30 metaphases were analyzed. Karyograms were interpreted by at least two Medical Technologists/Cytogeneticists and diagnoses were reported according to the International System for Human Cytogenomic Nomenclature (ISCN) 2016.

Data Interpretation and Validation
The clinical significance of the detected SNVs, InDels, and CNVs were interpreted in accordance with the guidelines of the American College of Medical Genetics and Genomics (ACMG) and were classified into five categories: pathogenic, likely pathogenic, variant of uncertain significance, likely benign, or benign. Prioritization of SNV/InDel samples in each case was based on the following criteria: 1) whether reported by ClinVAR or HGMD (human mutation gene database); 2) with a minor allele frequency ≤5% in the databases of ExAC (http://exac.broadinstitute.org) and gnomAD (https://gnomad.broadinstitute.org); 3) located in coding region and exon–intron junctions; 4) with damaging/intolerant or splicing-change effect suggested by multiple biological algorithms (SIFT, Polyphen-2, MutationTaster, Human Splicing Finder, and MaxEntScan); and 5) located in an OMIM disease-causing gene. For known mutations, correlation of ultrasound finding(s) with the reported phenotype(s) was conducted. For novel variants, the priority of further classification was conducted as 1) located gene was reported to be in autosomal dominant or X-linked dominant manner; 2) affecting gene was in autosomal recessive or X-linked recessive manner, and a homozygous variant or more than one variant (suspected compound heterozygosity) were found. CNV interpretation was conducted based on our reported study (Dong et al., 2016). Potential disease-causing mutations were selected for validation and parental confirmation when available. No guidelines were available for SV interpretation; thus, gene disruption or potential gene dysregulation by the disruption of regulatory elements or topological associated domains were used for further interpretation. Parental confirmation was conducted if available for determination of the mode of inheritance of the variants.

SNV/InDel/SV were validated by Sanger sequencing. Genomic reference sequences (hg19) from each putative variant/breakpoint region were used for web-based primer design with
RESULTS

Overall, we recruited 50 pregnancies with fetus with increased NT in the first-trimester Down syndrome screening. Thirty-seven CVS samples were collected from the first trimester, and AF samples were collected in later gestational weeks in the other 13 cases. Thirty-four cases were reported to have isolated increased NT with/without other soft markers (68.0%), and 16 cases were diagnosed with syndromic abnormalities (increased NT and fetal structural malformations, Table 1). All cases have undergone routine prenatal diagnosis by CMA, and 90% of these cases also have G-banded chromosome results available. CMA with/without karyotyping yielded diagnoses in eight cases, with pathogenic/likely pathogenic (P/LP) CNVs, providing a diagnostic yield of 16.0% (Figure 1 and Table 1).

### Numerical Disorders and CNVs

In this study, karyotyping identified four microscopic deletions/duplications, while CMA reported eight cases with P/LP CNVs and seven with variants of uncertain significant (VOUS or VUS, Supplementary Table S2). Compared with CMA results, GS not only detected all P/LP CNVs and VOUS detectable by CMA but also defined additional findings including a case of mosaic turner syndrome, a case of comprehensive delineation of CNV in one case with 16p11.2 recurrent deletion syndrome (Table 2), and two additional VOUS (Supplementary Table S2).

In 17NT0005, a fetus at the 12th gestational week with NT >14.3 mm presented with cystic hygroma. Normal CMA results were reported by the SNP-based platform and no karyotyping results were available (Figures 2A, B and Supplementary Figure S1). GS reported a mosaic turner syndrome with mosaic level around 40% (Figure 2C). Further validation by aCGH-based platform confirmed this finding and with consistent mosaic level estimated (Figure 2D). Mosaic turner syndrome was known to be the causative finding for the fetus with cystic hygroma, but it was missed by the original CMA in this study (Alpman et al., 2009). In the original CMA result, no decrease of copy ratio of the Y chromosome was indicated by the allele difference data, although it was slightly decreased compared with the one of the X chromosome based on the coverage difference data (Figure 2B). It indicated that SNP-based platform might not be sensitive enough for detection of mosaicism on chromosome Y. Since the DNA source of this sample was from CVS, we could not exclude the fact that the possibility of this mosaic turner syndrome was due to confined placental mosaicism. However, further confirmation by testing with AF sample was not possible as the pregnancy was terminated due to the severe presentation in the fetus (cystic hygroma).

In total, GS identified one mosaic turner syndrome and eight cases with P/LP microdeletions/microduplications (Table 2) in this group.

| Clinical indications | Number of cases | CMA with/without karyotyping | GS | P value |
|---------------------|-----------------|-----------------------------|----|---------|
|                     |                 | Diagnostic yield            |    |         |
|                     |                 | 95% C.I. (%)*               |    |         |
| Isolated (increased NT with/without other soft markers) | 34 (68%) | 5/34 (14.7%) | 5.0–31.1 | 10/34 (29.4%) | 15.1–47.5 | 0.144* |
| Syndromic (increased NT with other fetal structural malformations) | 16 (32%) | 3/16 (18.8%) | 4.0–45.6 | 6/16 (37.5%) | 15.2–64.6 | 0.433* |
| Overall | 50 | 8/50 (16%) | 7.2–29.1 | 16/50 (32%) | 19.5–46.7 | 0.061* |

*95% confidence interval was calculated by binomial exact calculation.
*Pearson chi-square.
*Fisher’s exact test.
TABLE 2 | Summary of numerical disorder and pathogenic or likely pathogenic CNVs detected.

| Case ID     | NT (mm) | Other sonographic findings               | Karyotype       | CMA                          | CMA result                  | GS                                | Pregnancy outcome* |
|-------------|---------|------------------------------------------|-----------------|------------------------------|------------------------------|----------------------------------|-------------------|
| 17NT0005    | 14.3    | –                                        | 46,XY           | SNP typing                   | Normal                       | seq[hg19] del(16p11.2)dn         | TOP                |
| 18NT0018    | 3.5     | –                                        | 46,XY           | aQGH                         | an[hg19] (1p11.2)38(29332358_30091372)x1 | chr16:g.29538256_30290160del     | Live birth; no    |
| 17BA0324    | 3.8     | –                                        | 46,XY,1q1h+     | aQGH                         | arr[hg19] 16p11.2(29832358_30091372)x1 | seq[hg19] del(20p13p12.3)       | –                 |
| 17BA0651    | 5.0     | –                                        | 46,XX,add(8)    | aQGH                         | arr[hg19] 16p11.2(184677_54961546)x1, | chr2:g.4936714_8674756del       | –                 |
| 18CO241     | 6.0     | Double cleft palate small left ventricle with a large ventricular septal defect dialated sigmoid colon | 46,XY,del(1)    | aQGH                         | seq[hg19] del(8)(p23.3p23.2)    | seq[hg19] del(20)(p13p12.3)     | –                 |
| 17CO070     | 7.4     | –                                        | 46,XY,del(2)    | aQGH                         | seq[hg19] del(20)(p13p12.3)    | chr1:g.10134_5523520del          | Miscarriage        |
| 17CO608     | 4.1     | Absent nasal bone and possible congenital heart disease | 46,XY,del(7)    | aQGH                         | seq[hg19] del(1)(q21q22)dn     | chr1:g.10134_5523520del          | Miscarriage        |
| 17CO963     | 5.4     | Pleural effusion and umbilical hernia     | 46,XX           | aQGH                         | seq[hg19] del(1)(q21q22)dn     | chr1:g.10134_5523520del          | Miscarriage        |
| 17C1600     | 4.4     | Right aortic arch                        | 46,XY           | aQGH                         | seq[hg19] del(1)(q21q22)dn     | chr1:g.10134_5523520del          | Miscarriage        |

*TOP refers to termination of pregnancy.

**SV Detection and the Potential Pathogenicity**

Apart from detecting CNV and point mutations, GS was able to identify structural rearrangements by utilizing paired-end reads. From Figure S2, it is clear that the couple decided to keep the pregnancy, and in 17NT0005, the second trimester revealed complex congenital heart disease with increased NT (10.9 mm), hydrosarca, and short limbs at the 12th week of gestation. Therefore, it was further classified as likely pathogenic (Figure A1), thus it was classified as a likely pathogenic cause of congenital heart disease with increased NT (10.9 mm), hydrosarca, and short limbs at the 12th week of gestation. In addition, we also identified five novel mutations in four samples, including variants in three autosomal dominant genes and one autosomal recessive gene (Table 3). For instance, in 18NT0003, a female fetus with increased NT (10.9 mm), hydrosarca, and short limbs at the 12th week of gestation was reported with normal karyotyping and CMA. GS detected a pathogenic mutation in an autosomal dominant disease-causing gene, which was reported to cause cardio-facio-cutaneous syndrome (OMIM #147920) in an autosomal dominant manner, commonly resulting in heart defects and renal malformations consistent with ciliopathies such as ciliary dyskinesia, primary ciliary dyskinesia, and Kartagener syndrome (OMIM #214800). The couple decided to keep the pregnancy, and in 17NT0005, the second trimester revealed complex congenital heart disease with increased NT (10.9 mm), hydrosarca, and short limbs at the 12th week of gestation. Therefore, it was further classified as likely pathogenic (Figure A1), thus it was classified as a likely pathogenic cause of congenital heart disease with increased NT (10.9 mm), hydrosarca, and short limbs at the 12th week of gestation. In addition, we also identified five novel mutations in four samples, including variants in three autosomal dominant genes and one autosomal recessive gene (Table 3). For instance, in 18NT0003, a female fetus with increased NT (10.9 mm), hydrosarca, and short limbs at the 12th week of gestation was reported with normal karyotyping and CMA. GS detected a pathogenic mutation in an autosomal dominant disease-causing gene, which was reported to cause cardio-facio-cutaneous syndrome (OMIM #147920) in an autosomal dominant manner, commonly resulting in heart defects and renal malformations consistent with ciliopathies such as ciliary dyskinesia, primary ciliary dyskinesia, and Kartagener syndrome (OMIM #214800).
Overall, two inversions and two insertions were detected among these 50 cases (Supplementary Table S4).

In 18NT0003 described above, GS also reported a cryptic balanced complex insertion seq[hg19]ins(2;12)(q33.2;q24.31) g.[chr2:203384219_203384293]inschr12:122757221_122907271cx]chr12:g.122757221_122907271del carrying a partial segment of gene CLIP1 from chromosome 12 to the site of BMPR2 in chromosome 2 (Supplementary Table S4, Figure 3D). The original fragment from chromosome 12 (seq[hg19] chr12:122757221_122907271) was 150.1 kb in size, but it was divided into 11 fragments with five segments lost when inserted to chromosome 2 (Supplementary Figure S3). There were 18 consecutive thymines (Ts) found in the breakpoint junction of the inserted site, not belonging to either chromosomes (2 and 12) (Figure 3D), indicating that the breakpoint repairing mechanism might be caused by non-homologous end joining with a cryptic insertion (Carvalho and Lupski, 2016). Parental confirmation by PCR and Sanger sequencing established this insertion to be a paternally inherited event. Regarding the potential pathogenicity, it has been known that mutations leading to loss of function in BMPR2 would cause Primary Pulmonary Hypertension 1 and/or Pulmonary Venocclusive Disease 1 (OMIM: #600799). However, we were unable to determine whether the disruption of BMPR2 was one of the causal factors of the fetal phenotype, since the pregnancy was terminated. We further followed up with the father (31 years old) and found sinus bradycardia by routine electrocardiograph. Although pulmonary hypertension may be later onset, sinus bradycardia might be one of the markers indicating pulmonary hypertension (Rajdev et al., 2012). Further follow-up is also ongoing.

For the other cryptic insertion and two inversions (Supplementary Table S4), since no OMIM genes were involved and no topological associated domains were disrupted, they were further classified as polymorphisms.

Overall Diagnostic Yield for Fetuses With Increased NT by GS

For these 50 cases, 68.0% of these cases had isolated increased NT with/without other soft markers. However, no significant difference of the diagnostic yields was found between isolated and syndromic groups (Table 1, chi-square test, $P = 0.5674$). In addition, GS provided a twofold diagnostic yield in all 50 cases compared with the routine test by CMA and/or karyotyping.

Comprehensive Detection and Delineation of the Variants in Individuals

In addition to the identification of individual variants (i.e., SNVs, CNVs and SVs), another advantage of using GS is to delineate the aberration regions involving various types of aberrations. For example, in 18NT0018, a male fetus with isolated increased NT, CMA reported a 259.0-kb de novo heterozygous deletion arr[hg19] 16p11.2(29832358_30091372)x1, which was diagnosed as 16p11.2 recurrent deletion syndrome (Lin et al., 2018). GS refined the breakpoints of the
### TABLE 3 | Summary of pathogenic or likely pathogenic mutations revealed by GS.

| Case     | NT (mm) | Other sonographic findings                                                                 | Gene          | Mutation and het/hom*                                                                 | Consequence | Inheritance mode | Disease association(s) [MIM #] | Pregnancy outcome | Inheritance confirmation |
|----------|---------|-------------------------------------------------------------------------------------------|---------------|---------------------------------------------------------------------------------------|-------------|------------------|-------------------------------|-------------------|--------------------------|
| 14C1232  | 3.73    | Mild ventricular disproportion                                                             | *ARMC4*       | NM_018076:c.1614_1615del (p.P538fs) het                                               | Frameshift  | AR               | Ciliary dyskinesia, primary, 23 (615451) | Live birth         | Pat                      |
|          |         |                                                                                            |               | NM_018076: c.C2306A                     (p.P769H) het                               | Missense    | AR               | Ciliary dyskinesia, primary, 23 (615451) | Live birth         | Mat                      |
| 15C0237  | 4.18    |                                                                                            | *ANKRD11*     | NM_001246: c.2404dupC                    (p.L802fs) het                               | Frameshift  | AD               | KBG syndrome (148050)                      | Live birth; newborn exam: low set ears, increased nuchal fold; right hand single transverse crease; bilateral clinodactyly; postnatal follow-up at three years old showed bilateral hearing loss (40 db) | De novo       |
| 15C0202  | 5.03    |                                                                                            | *GATA4*       | NM_002052:c.C1325T(p.A442V)            (p.A442V) het                               | Missense    | AD               | Atrial septal defect 2 (607941); Tetralogy of Fallot (187500) | Live birth         | Mat                      |
| 18NT019  | 3.5     |                                                                                            | *NSD1*        | NM_00254: c.3797-2A > G (p.D5492fs) het                                               | Splicing site| AD               | Sotos syndrome 1[117550]                  | –                 | –                        |
| 16C1953  | 10.9    | Large jugular lymphatic sac; cystic hygroma; absent ductus venosus a-wave; bilateral hand with bifi thumb | *BRAF*        | NM_004333: c.G1411T                     (p.V471F) het                               | Missense    | AD               | Noonan syndrome 7 (613706); Cardiofaciocutaneous syndrome (115150) | TOP               | –                        |
| 18NT003  | 12      | Hydrosarca; cystic hygroma; short long bones                                             | *COL2A1*      | NM_001844: c.G2950A                     (p.G984S) het                               | Missense    | AD               | Achondrogenesis, type II (200610)          | TOP               | De novo                  |
| 18NT018  | 3.5     | Reverse “a” wave in DV, absent nasal bone and possible congenital heart disease: single atrium, single ventricle, bilateral renal volume increased with polycystic changes | *KMT2D*       | NM_003482: c.16474delG                  (p.D5492fs) het                               | Frameshift  | AD               | Kabuki syndrome 1[147920]                 | TOP               | –                        |

*het/hom refer to heterozygous mutation or homozygous.

*Mat and Pat refer to maternally and paternally inherited, respectively.
FIGURE 3 |
CNV to a 751.9-kb de novo deletion seq[hg19] del(16p11.2) chr16:g.29538256_30290160del (Figure 4A) that involved the TBX6 gene (T-Box 6, Figure 4B) not covered by the CNV reported by CMA. Heterozygous deletion of TBX6 was further confirmed by qPCR experiment (Figure 4C) in the proband and the parents. The smaller CNV reported by CMA was contributed by the absence of probes in the region next to the reported region (Figure 4B). TBX6 is currently involved in 16p11.2 recurrent deletion syndrome (Lin et al., 2018) and is highly correlated with scoliosis if there was a presence of a hemizygous T-C-A haplotype (Wu et al., 2015; Liu et al., 2019a). However, there was no mutant allele detected for each of these common single-nucleotide polymorphisms (SNPs: rs2289292, rs3809624, and rs3809627) in the fetus. Further follow-up with the family: the pregnancy was kept and no scoliosis was found in the infant, echoing lower risk of having scoliosis in the absence of a hemizygous T-C-A haplotype in patient with 16p11.2 recurrent deletion syndrome (Wu et al., 2015; Liu et al., 2019a).

DISCUSSION

In this study, we applied GS for 50 fetuses with increased NT with/without other fetal structural malformations. In comparison, GS provided an overall diagnostic rate of 32.0%, which was a twofold increase compared to the current prenatal diagnosis tests (16.0%). Additional diagnoses include one mosaic turner syndrome, eight cases with P/LP CNVs (Table 2), and seven cases with P/LP point mutations (Table 3). In addition, GS reported two cryptic insertions and two inversions, and we further demonstrated the potential pathogenicity of disrupting OMIM disease-causing gene by the inserted site in the follow-up study. Overall, GS demonstrates the ability to detect the various disease-causing variants in human diseases such as fetuses with increased NT (Figure 5).

For the detection of numerical disorders and CNVs, GS detected additional findings including one case of mosaic turner syndrome and one case of comprehensive delineation of 16p11.2 recurrent deletion syndrome, compared with CMA (Table 2).
For the case with the mosaic turner syndrome (~40% mosaic level) additionally detected by GS (Figure 2), it was undetected by CMA possibly due to the algorithm employed for calling the copy number changes by calculating the allele differences. Further confirmation of this mosaic finding by using aCGH-based CMA platform shows the cross-platform differences of CMA testing (Haraksingh et al., 2017; Wang et al., 2019). Of note, in a routine setting, QF-PCR experiment was conducted prior to CMA for the detection of MCC and common aneuploidy. However, the missed detection of decreased copy ratio of the Y chromosome by QF-PCR in this case might be due to the low-level mosaicism presented (Shin et al., 2016). In addition, GS was able to delineate the 16p11.2 recurrent deletion, which included the disease-causing gene TBX6, the missed detection of which in this customized CMA platform was owing to the lack of probes located in the target region (Figure 4B). In this study, the detection results from only two CMA platforms were used for comparison and the missed detections and delineations described might be limited to these specific CMA platforms. A large-scale and systematic comparison of the performance of different currently available CMA platforms in prenatal diagnosis is warranted as certain platforms such as CytoScan HD and CytoSNP 850K have demonstrated to provide accurate breakpoints of CNVs detected and reliable detection of mosaicism, with a level greater than 20–30% (Haraksingh et al., 2017; Wang et al., 2019).

On top of the scope of current prenatal genetic diagnosis by karyotyping and CMA, GS also detected seven cases with P/LP SNVs and InDels, including three known pathogenic mutations/sites and five novel mutations (in four cases). The incidence of P/LP mutations in this study was 14.0%, which was higher than...
the newly reported studies utilizing trio-based WES (Lord et al., 2019; Petrovski et al., 2019). A possible reason is the limited sample size or echoing the message that GS is more powerful than WES for detecting exome variants, particularly for SNVs and InDels (Belkadi et al., 2015). However, no WES data were available for comparison in our study.

Current clinical guidelines for variants interpretation are available for SNVs/InDels and CNVs, but there are no guidelines available for SV interpretation. Our study demonstrates the feasibility of detecting SVs by utilizing paired-end reads from GS. With that, we were able to identify inversions and insertions and to show the potential pathogenicity in a paternally inherited insertion disruption of gene BMRP2. Follow-up study conducted in the father indicated a sinus bradycardia from routine electrocardiograph. Detection of such cryptic rearrangements would help us explore a “blind spot” using the routine methods. However, CNVs and SVs are predominantly mediated by repetitive elements [commonly >1 kb (van Heesch et al., 2013)], which causes difficulty in the identification of the flanking unique sequences by standard GS with small-insert libraries employed in this study (Chen et al., 2008; Carvalho and Lupski, 2016; Dong et al., 2018a). Further study with other approaches such as mate-pair sequencing might be an alternative method for identifying additional pathogenic SVs (Talkowski et al., 2012a; Dong et al., 2019), which is enriched in the disease groups (Talkowski et al., 2012b). Overall, apart from identifying individual genomic variants, GS also shows its advantages in comprehensively defining different mutation types in different alleles. It is supported by the absence of a hemizygous T-C-A haplotype in the region of 16p11.2 recurrent deletion syndrome (Wu et al., 2015; Liu et al., 2019a) (Figure 5).

Overall, by taking together the various genomic variants, the diagnostic rates of GS were not significantly different between the isolated and syndromic groups (Table 1). For the isolated group, GS provided a diagnostic yield as 29.4%, which was significantly higher than previously reported (Lord et al., 2019). One of the reasons might be owing to the small sample size. Nonetheless, our current data truly show a higher diagnostic yield. Further study with a larger sample size is warranted. However, there were still 34 cases without a positive diagnosis by genome sequencing. Pregnancy outcomes were available for 18 cases, 7 (38.9%) of which were terminated pregnancies due to severe fetal malformations, such as pleural effusion, multicystic dysplastic kidneys, and complex congenital heart disease. It indicates that genome sequencing is still not revealing all the causative variants and the clinical decision of continuing or termination of pregnancy is largely dependent on the severity of fetal malformation(s) found in each particular case. Nonetheless, reanalysis of the GS data frequently upon updating literatures might be able to increase the genetic diagnosis (Liu et al., 2019b) and, thus, provide the causative answers for the family.

In this study, we aimed to evaluate the feasibility of applying GS for prenatal diagnosis in fetuses with increased NT. Apart from the increased diagnostic yield, the requirement of DNA amount as input for GS (100 ng) was less, compared with CMA (250 ng for CytoScan 750K or 300 ng for the 8x60K fetal chip), which would further facilitate GS in prenatal diagnosis, particularly for the AF samples from early gestational weeks. In addition, in comparison with the methods for routine prenatal diagnosis (CMA and karyotyping), GS would be able to provide a comparable turnaround time of 10 working days from DNA preparation to variant validation (Figure 1). Although the reagent cost of GS is less than 1000 USD per case, the demands of computational resources and labor costs for data analysis and interpretation are still higher than routine methods (Figure 1). Parental confirmation is important for determination of the variants’ pathogenicity. In this study, we applied GS only for the proband and conducted parental confirmation by Sanger sequencing, which was laborious. Although applying trio-based GS testing would be helpful for variant filtering in initial data analysis, it would triplicate the cost, thus preventing the value of clinical application.

Regarding the interpretation of genomic variants, similarly with the prenatal studies by WES, even with parental confirmation, GS study would still yield a number of VOUS, the pathogenicity and clinical significance of which are still uncertain. One of the reasons would be lack of clinical symptom(s) in early pregnancy; follow-up with detailed diagnosis would be warranted. For instance, in 18NT003, a fetus with increased NT, hydrosarca, and short limbs, GS reported a known LP mutation in COL2A1 that might already explain the malformation. In addition, GS with parental confirmation also reported another two variants in a compound heterozygosity manner, including a paternally inherited heterozygous variant NM_015662:c.A3089G(p. D1030G) and a maternally inherited heterozygous variant NM_015662:c.G449C(p.G150A) in gene IFT172 (Figures 3B, C). Mutations in IFT172 are known to cause retinitis pigmentosa (OMIM: #616394) or short-rib thoracic dysplasia (OMIM: #615630); the latter might be also be partially correlated with the fetal phenotype but might only present in later gestation. However, further confirmation of the pathogenicity by correlating the phenotype in later gestational weeks was not possible as the pregnancy was terminated. Nonetheless, GS still provides a comprehensive foundation for gene discovery. Moreover, one limitation of this study was the retrospective approach and the limited sample size, a prospective back to back in comparison of GS’s performance with routine prenatal diagnosis approaches with a larger sample size, and other clinical indications are warranted in the near future.

In conclusion, our study demonstrates that applying GS in fetuses with increased NT can provide comprehensive detection of various disease-causing genomic variants, including SNVs, InDels, CNVs, and structural rearrangements. Compared with current routine prenatal diagnosis approaches, GS not only shows increased sensitivity for detecting mosaic numerical disorders and comprehensive delineation of P/LP CNVs but also provides the ability of identifying causative point mutations and balanced structural rearrangements that are beyond the detection scope of current prenatal diagnosis protocols. Although future prospective studies with larger sample sizes are warranted, given the comparable turnaround time and less DNA required in addition to the increased diagnostic yield, our study provides the first strong evidence to facilitate GS in prenatal diagnosis, particularly in fetuses with increased NT.
DATA AVAILABILITY

Genome sequencing data used in this study have been made available in the CNGB Nucleotide Sequence Archive (CNSA: https://db.cngb.org/cnsa/) under the accession number CNP0000437.

ETHICS STATEMENT

The study protocol was approved by the Ethics Committee of the Joint Chinese University of Hong Kong–New Territories East Cluster Clinical Research Ethics Committee (CREC Ref. No. 2016.713), Jinan University, and Guangzhou Medical University.

AUTHOR CONTRIBUTIONS

KWC, MC, TYL, and ZD designed the study. HW, JC, RZ, OC, YZ, and TYL collected the samples and followed up. KWC, MS, ZY, YC, YK, and ZD performed the analysis and data interpretation.

MS, HY, YW, SC, and MHKC conducted the validation. KWC, HW, MS, JC, and ZD wrote the manuscript.

FUNDING

This project is supported by the National Natural Science Foundation of China (81741009, 81671470, and 31801042), the Health and Medical Research Fund (04152666 and 01120766), the Guangzhou Science and Technology Program (2014 Y2-00551, 201504282321393, 201604020078, and 201604020091), and the National Key Research and Development Program of China (2018YFC1004104).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2019.00761/full#supplementary-material.

REFERENCES

Chow, T. Y. L., Choy, K. W., Kwok, Y. K., Cheng, Y. K., Wong, K. M., Wong, H. K., Leung, K. O., et al. (2017). Low-pass whole-genome sequencing for detection of various genomic variants in one single assay. Gigascience 6, 1–9. doi: 10.1093/gigascience/gix024

Huang, J., Liang, X., Xuan, Y., Geng, C., Li, Y., Lu, H., et al. (2017). A reference genome model for prenatal diagnosis of fetuses with monosomy X. Genome Res. 27, 1053–1065. doi: 10.1101/gr.225044.116

Yu, M. H. C., et al. (2018). Identifying the genetic causes for prenatally diagnosed structural congenital anomalies (SCAs) by whole-exome sequencing (WES). BMC Med. Genomics 11, 93. doi: 10.1186/s12920-018-0409-z

Leung, T. Y., Vogel, I., Lau, T. K., Chong, W., Hyett, J. A., Petersen, O. B., et al. (2016). Mutation update for COL2A1 gene variants associated with type II collagenopathies. Hum. Mutat. 37, 7–15. doi: 10.1002/humu.22915

Elkayed, A., Beyaert, R., Vermeulen, L., D’Hooghe, T., et al. (2009). Genetic and functional characterization of congenital adrenal hyperplasia due to mutations in the CYP21A2 gene. Hum. Mol. Genet. 18, 3095–3110. doi: 10.1093/hmg/ddp238

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2019.00761/full#supplementary-material.
of fetal aneuploidies in chorionic villus sampling in a single institution. Obstet. Gynecol. 59, 444–453. doi: 10.5468/ogs.2016.59.6.444
Sinaij, P., Chitayat, D., Rosman, M., Wazim, S., Carmona, S., Ryan, G., et al. (2019). Increased nuchal translucency: results from microarray and RASopathy disorders testing. Ultrasound Obstet. Gynecol. doi: 10.1002/uog.20352
Socolov, D., Socolov, R., Gorduza, V. E., Butureanu, T., Stanculescu, R., Caruleanu, A., et al. (2017). Increased nuchal translucency in fetuses with a normal karyotype-diagnosis and management: an observational study. Medicine (Baltimore) 96, e7521. doi: 10.1097/MD.0000000000007521
Tolkowski, M. E., Ordulu, Z., Pillalamarri, V., Benson, C. B., Blumenthal, I., Connolly, S., et al. (2012a). Clinical diagnosis by whole-genome sequencing of a prenatal sample. N. Engl. J. Med. 367, 2226–2232. doi: 10.1056/NEJMoa1208594
Tolkowski, M. E., Rosenfeld, J. A., Blumenthal, I., Pillalamarri, V., Chiang, C., Heilbut, A., et al. (2012b). Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. Cell 149, 525–537. doi: 10.1016/j.cell.2012.03.028
Van Heesch, S., Kloosterman, W. P., Lansu, N., Ruzijs, F. P., Levandowski, E., Lee, C. C., et al. (2013). Improving mammalian genome scaffolding using large insert mate-pair next-generation sequencing. BMC Genomics 14, 257. doi: 10.1186/1471-2164-14-257
Wang, J. C., Radcliff, J., Coe, S. J., and Mahon, L. W. (2019). Effects of platforms, size filter cutoffs, and targeted regions of cyogenic microarray on detection of copy number variants and uniparental disomy in prenatal diagnosis: results from 5026 pregnancies. Prenat. Diagn. 39, 137–156. doi: 10.1002/pd.5375
Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164. doi: 10.1093/nar/gkq603
Wu, N., Ming, X., Xiao, J., Wu, Z., Chen, X., Shinawi, M., et al. (2015). TBX6 null variants and a common hypomorphic allele in congenital scoliosis. N. Engl. J. Med. 372, 341–350. doi: 10.1056/NEJMoa1406829
Yang, X., Li, R., Fu, F., Zhang, Y., Li, D., and Liao, C. (2017). Submicroscopic chromosomal abnormalities in fetuses with increased nuchal translucency and normal karyotype. J. Matern. Fetal. Neonatal. Med. 30, 194–198. doi: 10.3109/14767058.2016.1168394

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Choy, Wang, Shi, Chen, Yang, Zhang, Yan, Wang, Chen, Chau, Cao, Chan, Kwok, Zhu, Chen, Leung and Dong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.